AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Thu, 04 Jun 2026 18:09:49 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/genomic-testing-gaps-chemotherapy-decisions-in-young-women-with-hr-breast-cancer-mitali-shah-mdhttps://www.ajmc.com/view/genomic-testing-gaps-chemotherapy-decisions-in-young-women-with-hr-breast-cancer-mitali-shah-md<![CDATA[Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.]]>Thu, 04 Jun 2026 17:15:35 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/oz-white-house-briefing-touts-drug-savings-and-fraud-cleanup-but-data-tell-a-nuanced-storyhttps://www.ajmc.com/view/oz-white-house-briefing-touts-drug-savings-and-fraud-cleanup-but-data-tell-a-nuanced-story<![CDATA[During a White House briefing, Mehmet Oz, MD, discussed the expansion of Trump Rx and crackdowns on duplicate ACA enrollment and fraudulent hospice programs.]]>Thu, 04 Jun 2026 17:03:01 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/what-30-years-of-oncology-trial-data-reveal-about-racial-representation-rahman-olusoji-mbbshttps://www.ajmc.com/view/what-30-years-of-oncology-trial-data-reveal-about-racial-representation-rahman-olusoji-mbbs<![CDATA[An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.]]>Thu, 04 Jun 2026 17:01:34 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/what-do-we-do-with-these-prices-ushering-in-the-next-phase-of-price-transparency-innovation-in-medicare-advantagehttps://www.ajmc.com/view/what-do-we-do-with-these-prices-ushering-in-the-next-phase-of-price-transparency-innovation-in-medicare-advantage<![CDATA[The problem is not that price transparency itself has failed, but rather that policy makers have focused their efforts on the wrong place.]]>Thu, 04 Jun 2026 16:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/plastic-in-personal-care-products-tied-to-skin-disease-and-environmental-pollution-review-findshttps://www.ajmc.com/view/plastic-in-personal-care-products-tied-to-skin-disease-and-environmental-pollution-review-finds<![CDATA[Everyday skincare may expose you to microplastics and plastic-linked chemicals tied to skin disease and hormone disruption; dermatologists urge safer products and packaging.]]>Thu, 04 Jun 2026 15:46:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/alexa-simon-meara-md-ms-on-immunotherapy-collaboration-beyond-siloshttps://www.ajmc.com/view/alexa-simon-meara-md-ms-on-immunotherapy-collaboration-beyond-silos<![CDATA[Alexa Simon Meara, MD, MS, discusses breaking down silos between academic and community oncology to improve immunotherapy care and irAE management.]]>Thu, 04 Jun 2026 14:57:05 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/enhancing-chronic-kidney-disease-treatment-with-guideline-directed-medical-therapies-through-electronic-alert-systems-and-integrated-care-management-initiativeshttps://www.ajmc.com/view/enhancing-chronic-kidney-disease-treatment-with-guideline-directed-medical-therapies-through-electronic-alert-systems-and-integrated-care-management-initiatives<![CDATA[This publication was developed with the support of Boehringer Ingelheim Pharmaceuticals, Inc.]]>Thu, 04 Jun 2026 14:51:22 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/clinical-and-economic-value-of-entyvio-vedolizumab-implications-for-ulcerative-colitis-and-crohn-disease-managementhttps://www.ajmc.com/view/clinical-and-economic-value-of-entyvio-vedolizumab-implications-for-ulcerative-colitis-and-crohn-disease-management<![CDATA[This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,.]]>Thu, 04 Jun 2026 13:15:23 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/real-world-weight-loss-with-injectable-semaglutide-vs-dulaglutide-for-diabeteshttps://www.ajmc.com/view/real-world-weight-loss-with-injectable-semaglutide-vs-dulaglutide-for-diabetes<![CDATA[In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.]]>Thu, 04 Jun 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/how-often-do-health-insurers-deny-doctor-recommended-carehttps://www.ajmc.com/view/how-often-do-health-insurers-deny-doctor-recommended-care<![CDATA[Coverage denials delay care, drive patients into debt, and erode trust in insurers—yet nearly half of affected patients never appeal. ]]>Thu, 04 Jun 2026 04:01:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/new-data-support-pimicotinib-as-durable-for-rare-tenosynovial-giant-cell-tumorhttps://www.ajmc.com/view/new-data-support-pimicotinib-as-durable-for-rare-tenosynovial-giant-cell-tumor<![CDATA[Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.]]>Wed, 03 Jun 2026 20:33:34 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/surgery-for-diabetic-gastroparesis-may-improve-hba1c-and-reduce-complicationshttps://www.ajmc.com/view/surgery-for-diabetic-gastroparesis-may-improve-hba1c-and-reduce-complications<![CDATA[Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications. ]]>Wed, 03 Jun 2026 20:30:49 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/focus-shifts-to-toxicity-management-gaps-as-melanoma-survival-improves-igor-puzanov-md-mscihttps://www.ajmc.com/view/focus-shifts-to-toxicity-management-gaps-as-melanoma-survival-improves-igor-puzanov-md-msci<![CDATA[From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.]]>Wed, 03 Jun 2026 20:30:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/acoramidis-shows-durable-benefit-at-54-months-in-attr-cmhttps://www.ajmc.com/view/acoramidis-shows-durable-benefit-at-54-months-in-attr-cm<![CDATA[Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.]]>Wed, 03 Jun 2026 20:13:39 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/asco-2026-spotlights-unmet-needs-across-cancer-carehttps://www.ajmc.com/view/asco-2026-spotlights-unmet-needs-across-cancer-care<![CDATA[ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens. ]]>Wed, 03 Jun 2026 19:56:58 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/musculoskeletal-quality-collaborative-improves-value-based-health-care-delivery-across-hospital-systemhttps://www.ajmc.com/view/musculoskeletal-quality-collaborative-improves-value-based-health-care-delivery-across-hospital-system<![CDATA[Implementation of surgeon-led Musculoskeletal Quality Collaborative protocols reduced high-cost consumable utilization without compromising patient safety. Systemwide collaboratives can reduce high-cost consumable utilization while maintaining low infection rates.]]>Wed, 03 Jun 2026 19:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/what-managed-care-should-watch-at-ada-2026-scientific-sessionshttps://www.ajmc.com/view/what-managed-care-should-watch-at-ada-2026-scientific-sessions<![CDATA[GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.]]>Wed, 03 Jun 2026 18:59:21 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/odronextamab-plus-chop-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-matthew-matasar-mdhttps://www.ajmc.com/view/odronextamab-plus-chop-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-matthew-matasar-md<![CDATA[OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.]]>Wed, 03 Jun 2026 17:17:29 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/social-needs-screening-and-supplemental-benefits-in-medicare-advantagehttps://www.ajmc.com/view/social-needs-screening-and-supplemental-benefits-in-medicare-advantage<![CDATA[The authors describe Medicare Advantage plans that screen for and provide supplemental benefits addressing social needs and explore how these benefits meet communities’ social needs.]]>Wed, 03 Jun 2026 17:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/sudden-death-in-hfpef-often-preceded-by-clinical-declinehttps://www.ajmc.com/view/sudden-death-in-hfpef-often-preceded-by-clinical-decline<![CDATA[A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF. ]]>Wed, 03 Jun 2026 16:07:16 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/implant-showed-sustained-anatomical-visual-benefits-in-dmehttps://www.ajmc.com/view/implant-showed-sustained-anatomical-visual-benefits-in-dme<![CDATA[The fluocinolone acetonide intravitreal implant showed durable improvements in anatomical and functional outcomes over a follow-up period of 36 months.]]>Wed, 03 Jun 2026 15:36:53 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/community-advanced-therapy-access-drives-equity-fran-gregory-pharmdhttps://www.ajmc.com/view/community-advanced-therapy-access-drives-equity-fran-gregory-pharmd<![CDATA[Advanced therapies must expand into community settings to improve access and address health equity gaps.]]>Wed, 03 Jun 2026 15:26:45 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/heat-exposure-may-triple-us-cardiovascular-disease-burden-by-2050https://www.ajmc.com/view/heat-exposure-may-triple-us-cardiovascular-disease-burden-by-2050<![CDATA[Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.]]>Wed, 03 Jun 2026 15:12:58 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/high-out-of-pocket-costs-raise-food-insecurity-risk-by-up-to-90-in-households-with-childrenhttps://www.ajmc.com/view/high-out-of-pocket-costs-raise-food-insecurity-risk-by-up-to-90-in-households-with-children<![CDATA[Even spending just 5% of income on medical costs raises food insecurity risk by 80% for families with children, study finds.]]>Wed, 03 Jun 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-issues-complete-response-letter-for-cingulate-s-once-daily-adhd-drug-ctx-1301https://www.ajmc.com/view/fda-issues-complete-response-letter-for-cingulate-s-once-daily-adhd-drug-ctx-1301<![CDATA[Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.]]>Wed, 03 Jun 2026 14:56:58 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/making-every-aml-diagnosis-a-path-to-cure-karilyn-larkin-mdhttps://www.ajmc.com/view/making-every-aml-diagnosis-a-path-to-cure-karilyn-larkin-md<![CDATA[Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.]]>Wed, 03 Jun 2026 14:30:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/new-french-psoriasis-guidelines-add-biologics-comorbidity-guidance-to-algorithmhttps://www.ajmc.com/view/new-french-psoriasis-guidelines-add-biologics-comorbidity-guidance-to-algorithm<![CDATA[The update makes biologics first-line treatment, adds comorbidity management guidance, and aligns practice with evolving European guidelines for psoriasis.]]>Wed, 03 Jun 2026 14:16:03 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/availability-of-hospital-financial-assistance-documents-in-non-english-languageshttps://www.ajmc.com/view/availability-of-hospital-financial-assistance-documents-in-non-english-languages<![CDATA[A cross-sectional study of online financial documents among hospitals in linguistically diverse core-based statistical areas found that nonprofit and system-affiliated hospitals have superior language access.]]>Wed, 03 Jun 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/clinical-burden-and-emerging-anti-vegf-therapies-in-retinal-vascular-diseaseshttps://www.ajmc.com/view/clinical-burden-and-emerging-anti-vegf-therapies-in-retinal-vascular-diseases<![CDATA[Explore how extended anti‑VEGF dosing cuts clinic burden, affects costs, and reveals key evidence gaps for AMD, DME, and RVO.]]>Wed, 03 Jun 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/access-and-evidence-gaps-in-retinal-vascular-diseaseshttps://www.ajmc.com/view/access-and-evidence-gaps-in-retinal-vascular-diseases<![CDATA[Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.]]>Wed, 03 Jun 2026 12:00:00 GMTAJMCusAJMC Articles